The Biotechnology and Human Health Sector: real potential to create economic value in the Paris Region
The Paris Region is the leading scientific and technological region in Europe with 7.5%of European internal R&D expenditure.
It also is a key player, unparalleled in the country, bringing together all players working in each of the stages of the development chain for therapeutic and diagnostic products, devices and services, from academic and clinical research through the AP-HP hospital network (unique in Europe) to large pharmacy and imaging companies, YICs (Young Innovative Companies), SMEs involved in biotechnology and health technologies, contract research organisations (CROs), higher educational institutions (universities and schools) and health safety authorities.
The Paris Region has many strong-points that make it the “European leader” in the industry for diagnostic and therapeutic innovation and in leading-edge health technology.
A project supporting 330 innovative SMEs in the “biotechnology and human health” sector.
A Biotech Santé cluster development project supported by the Paris Region and the State is currently in progress.
This 3-year project (2011 – 2013) targets 330 Paris Region SMEs in the health and biotechnology sector and has set the following priorities:
- To organise the structure of healthcare SMEs in the region into sectors according to technological offering or therapeutic objective within the framework of the Paris Region sector plan,
- To optimise access to private and public (regional, national, European) funding for SMEs and promote the development of their activities (R&D and turnover), both nationally and internationally. To optimise access for SMEs to human resources to meet their needs.
Medicen Paris Region, the global leading-edge technology competitiveness cluster for healthcare and new therapies is the leader of this project.
5 development levers